The Effect And Safety Evaluation Of Ondaparinuxna On Non-ST-segment Elevation Acute Coronary Syndromes

Objective:Intention to evaluate the effectiveness and security of FondaparinuxNa used in china non-ST-segment elevated acute coronary syndromes(NSTACS)by in hospital and follow up investigation.Methods:Continuous charge187NSTACS Patients randomized divided into FondaParinuxNa(study group)or the EnoxaParine(control group)which are all undergoing anticoagulant therapy.Totalmortality,composite events,total bleeding events,Prothrombin time (PT),activatedPartial thromboPlastin enzyme time (APTT), creatine kinase isoenzyme (CK-MB) for hospital observation,the first attack coronary ischemic events outside hospital were followed up for outcome events.Results:1.The total mortality rate of study grou-p is higher than the control group (P<0.05).Adjusted mortality between the two grouP has no statistically significant difference(P>0.05).2.The incidence of total bleedi-ng events between the two grouP has no statistically significant difference(P>0.05),But the study group TIMI severe bleeding incidence was higher than the controlgroup3.Both of PT, APTT and CK-MB,has no statistically significant difference(P>0.05).4.The cumulative incidence of coronary ischemic events in the two groups outside the hosPital has also no significant statistical difference(P>0.05).Conclusion:The FondaparinuxNa effectiveness and safety are all reliable,which could be used inChina NSTACS patients.